Company Encyclopedia
View More
name
ImmuCell
ICCC.US
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
1.945 T
ICCC.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking46/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.27%B
    • Profit Margin8.37%B
    • Gross Margin42.92%B
  • Growth ScoreB
    • Revenue YoY16.49%B
    • Net Profit YoY160.97%A
    • Total Assets YoY2.88%C
    • Net Assets YoY12.83%B
  • Cash ScoreB
    • Cash Flow Margin1195.06%B
    • OCF YoY16.49%B
  • Operating ScoreB
    • Turnover0.62B
  • Debt ScoreB
    • Gearing Ratio34.83%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immucell CEO Makes a Bold Move with New Stock Purchase!

    Immucell's President & CEO, Paul Francis Olivier te Boekhorst, purchased 9,785 shares valued at $48,546 on December 3, 2025. The company reported a net income of $1.8 million for the nine months ending September 30, 2025, compared to a net loss of $2.7 million in 2024. Gross margin increased to 43% in Q3 2025 from 26% in Q3 2024. Domestic sales grew by 2% in Q3 2025 compared to Q3 2024, but total product sales declined by 8% due to shipment timing and allocation issues. Analysts maintain a cautious outlook due to mixed financial performance.

    Tip Ranks·
    US
    ICCC
    +4.80%
    Tip Ranks·
    US
    ICCC
    +4.80%

    ImmuCell CEO Paul Francis Olivier te Boekhorst Acquires Common Shares

    ImmuCell Corporation's CEO, Paul Francis Olivier te Boekhorst, has acquired common shares of the company. This event was reported through EDGAR by the U.S. Securities and Exchange Commission. The news is informational and not financial advice.

    Reuters·
    US
    ICCC
    +4.80%
    Reuters·
    US
    ICCC
    +4.80%

    Chmn Tomsche Buys 3,266 ($15.6K) Of Immucell Corp [ICCC]

    Tomsche David Scott Chairman of the Board of Immucell Corp [ICCC] filed a Form 4 on November 28, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/25/25TransactionPurchaseShares3,266Price$4.76Value$15,554Ending Holdings: 131,387 (52,720 - Direct, 78,667 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ICCC
    +4.80%
    Reuters·
    US
    ICCC
    +4.80%

    ImmuCell Director David Scott Tomsche Reports Acquisition of Common Shares

    David Scott Tomsche, Director of ImmuCell Corporation, has acquired common shares of the company. This event was reported through a filing accessible via EDGAR, the U.S. SEC's system. The information is provided by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ICCC
    +4.80%
    Reuters·
    US
    ICCC
    +4.80%

    ImmuCell (NASDAQ:ICCC) Announces Quarterly Earnings Results

    ImmuCell (NASDAQ:ICCC) reported a quarterly loss of $0.02 per share, with a return on equity of 6.25% and a net margin of 6.23%. The stock price fell by $0.08 to $6.05. Weiss Ratings downgraded the stock to a 'sell' rating. Geode Capital Management increased its stake in the company by 4.2% in the second quarter. ImmuCell focuses on animal health products for dairy and beef cattle.

    Market Beat·
    US
    ICCC
    +4.80%
    Market Beat·
    US
    ICCC
    +4.80%
    © 2025 Longbridge｜Disclaimer